Grants and Contributions:
Title:
Sustained release form targeting wet age-related macular degeneration
Agreement Number:
995494
Agreement Value:
$22,984.00
Agreement Date:
Sep 1, 2022 - Jan 31, 2023
Description:
Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. Scientific and engineering resources will perform work on
the development of a novel compound for the treatment of Neovascular age-related macular degeneration (nAMD). The project will require synthesizing novel compounds and performing materials characterization and in vitro evaluations to assess for potential lead compounds for the next stages of development.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 1L7
Reference Number:
172-2022-2023-Q2-995494
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
760459073
Recipient Type:
For-profit organization
Recipient's Operating Name:
Ripple Therapeutics
Recipient's Legal Name:
Ripple Therapeutics Corp.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541